Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Acquisitions News

12/17/2024
AcquisitionsDealsGlaucomaNewsletter
Bausch + Lomb Acquires Elios Vision, Developer of Excimer Laser Trabeculostomy
Bausch + Lomb Acquires Elios Vision, Developer of Excimer Laser Trabeculostomy

Bausch + Lomb announced Dec. 11 that an affiliate had acquired Elios Vision, developer of the Elios excimer laser trabeculostomy procedure for glaucoma. No financial details were disclosed. Elios’ ...

7/23/2024
AcquisitionsDealsFundingNewsletter
Q2-2024 Ophthalmic Deals Total More Than $1.6 Billion, Include One Strategic Purchase
Q2-2024 Ophthalmic Deals Total More Than $1.6 Billion, Include One Strategic Purchase

Ophthalmic deals in Q2-2024 reached over $1.6 billion and involved 19 transactions. This compares with $7.0 billion from 25 transactions in Q2-2023 and $2.0 billion from 17 transactions in Q1-2024....

7/23/2024
AcquisitionsDealsNewsletterPharma
ANI to Acquire Alimera Sciences, Maker of Iluvien and Yutiq, for $381 Million
ANI to Acquire  Alimera Sciences, Maker of Iluvien and Yutiq, for $381 Million

ANI Pharmaceuticals announced June 24 that it would acquire Alimera Sciences, maker of Iluvien and Yutiq, in a deal worth $381 mil-lion up front. The deal is expected to close in late Q3-2024, the ...

6/28/2024
AcquisitionsBreakingDealsPharma
ANI Pharmaceuticals to Acquire Alimera Sciences, Maker of Iluvien and Yutiq, for $381 Million
ANI Pharmaceuticals to Acquire Alimera Sciences, Maker of Iluvien and Yutiq, for $381 Million

ANI Pharmaceuticals announced June 24 that it would acquire Alimera Sciences, maker of Iluvien and Yutiq, in a deal worth $381 million up front. The deal is expected to close in late Q3-2024, the c...

5/22/2024
AcquisitionsDealsGlaucomaLaserNewsletter
Alcon to Acquire Glaucoma Laser Company Belkin Vision for up to $335M
Alcon to Acquire Glaucoma Laser Company Belkin Vision for up to $335M

Alcon is acquiring Israel’s Belkin Vision, maker of the Eagle laser for glaucoma, for up to $335 million, according to reports. The value of the transaction was first estimated in a story dated May...

5/22/2024
AcquisitionsNewsletterProsthesisRetina
California-Based Science Corporation Acquires Pixium Vision’s Prima Implant
California-Based Science Corporation Acquires Pixium Vision’s Prima Implant

Science Corporation, of Alameda, California, reported April 25 that it had acquired the IP and related assets for the Prima retinal implant, developed by Pixium Vision SA, of France. Terms of the d...

5/10/2024
AcquisitionsBreakingDealsGlaucomaLaser
Alcon to Acquire Glaucoma Laser Company Belkin Vision for up to $335 Million
Alcon to Acquire Glaucoma Laser Company Belkin Vision for up to $335 Million

Alcon is acquiring Israel’s Belkin Vision, maker of the Eagle laser for glaucoma, for up to $335 million, according to reports. The value of the transaction was first estimated in a story dated May...

5/3/2024
AcquisitionsBreakingDealsLow VisionProsthesisRetina
California-Based Science Corporation Acquires Pixium Vision’s Prima Implant
California-Based Science Corporation Acquires Pixium Vision’s Prima Implant

Science Corporation, of Alameda, California, reported April 25 that it had acquiredthe IP and related assets for the Prima retinal implant, developed by Pixium Vision SA, of France. Terms of the de...

4/24/2024
AcquisitionsDealsNewsletterRetina
ABVC BioPharma Sells Global Rights to Vitreous Substitute to ForSeeCon Eye for $30 Million Up Front
ABVC BioPharma Sells Global Rights to Vitreous Substitute to ForSeeCon Eye for $30 Million Up Front

ABVC BioPharma announced March 26 that it had agreed to license its ophthalmology pipeline, including the vitreous substitute candidate Vitargus, to ForSeeCon Eye. ABVC, of Fremont, California, say...

2/22/2024
AcquisitionsDeviceNewsletterRetinaSurgical
Retinal Device Market Awaits Technological Impact of Zeiss’ DORC Acquisition
Retinal Device Market Awaits Technological Impact of Zeiss’ DORC Acquisition

Carl Zeiss Meditec’s acquisition of DORC (Dutch Ophthalmic Research Center) will change the players in the retinal surgical equipment market, but whether it will lead to any major changes in market...

2/22/2024
AcquisitionsDealsNewsletterRetina
Sandoz Acquires Biosimilar Cimerli from Coherus for $170M Up Front
Sandoz Acquires Biosimilar Cimerli from Coherus for $170M Up Front

Swiss drugmaker Sandoz announced Jan. 22 that it had signed an agreement to acquire the US ranibizumab (Lucentis) biosimilar Cimerli from Coherus BioSciences for $170 million up front. The deal inc...

9/21/2023
AcquisitionsDealsEuropeNewsletterSurgical
BVI Expands Presence in Spain and Portugal with Acquisition of Medical Mix
BVI Expands Presence in Spain and Portugal with Acquisition  of Medical Mix

BVI Medical announced Sept. 6 that it had acquired Medical Mix, a leading supplier of ophthalmic surgical devices in Spain and Portugal. No financial details were provided. Medical Mix, of Barcelon...

9/8/2023
AcquisitionsBreakingDealsEuropeSurgical
BVI Expands Presence in Spain and Portugal with Acquisition of Medical Mix
BVI Expands Presence in Spain and Portugal with Acquisition of Medical Mix

BVI Medical announced Sept. 6 that it had acquired Medical Mix, a leading supplier of ophthalmic surgical devices in Spain and Portugal. No financial details were provided. Medical Mix, of Barcelon...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more